Cargando…
Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study
To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18–87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to t...
Autores principales: | Yang, Chin-Yi, Lai, Po-Ju, Chen, Chun-Bing, Chan, Tom C., Hui, Rosaline Chung-Yee, Huang, Yu-Huei, Tseng, Han-Chi, Lin, Shang-Hung, Lu, Chun-Wei, Lee, Hua-En, Lin, Jing-Yi, Chi, Min-Hui, Tsai, Ming-Feng, Hwang, Yih-Shiou, Wang, Chuang-Wei, Chu, Chia-Yu, Chung, Wen-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605350/ https://www.ncbi.nlm.nih.gov/pubmed/36294530 http://dx.doi.org/10.3390/jcm11206209 |
Ejemplares similares
-
Dupilumab for atopic dermatitis
Publicado: (2019) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023) -
Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan
por: CHAN, Tom C., et al.
Publicado: (2021) -
Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis
por: Su, Chia-Jui, et al.
Publicado: (2021)